Novavax's stock is highly volatile due to the company's instability and inconsistent financial results. Sanofi has partnered with the company, and that has sparked a wave of excitement in Novavax's stock.
Penny stocks have the tendency to surprise when it comes to delivering stellar returns at the blink of an eye. A good example is Novavax (NASDAQ: NVAX ) that has delivered 203% returns for year-to-date.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax, Inc. (NASDAQ:NVAX ) Jefferies 2024 Global Healthcare Conference June 6, 2024 12:30 PM ET Company Participants John Jacobs - President and CEO Filip Dubovsky - Chief Development Officer Jim Kelly - CFO Conference Call Participants Roger Song - Jefferies Roger Song All right. Good afternoon, everyone.
Novavax NASDAQ: NVAX is a drug and vaccine manufacturer in the healthcare sector known for its efforts in the COVID-19 vaccine market. Novavax's stock price has experienced a remarkable surge recently, attracting significant attention from investors and Novavax's analyst community.
Vaccine maker Novavax (NASDAQ: NVAX ) saw its shares jump 18% on June 5 and another 20% in pre-market trade this morning. NVAX stock is up over 300% year-to-date.
Novavax stock zipped to a nearly two-year high Thursday after the FDA set a potential approval date for its Covid vaccine in April.
Novavax (NASDAQ: NVAX) stock price has gone parabolic this year, making it one of the best-performing companies in New York. It has soared by over 335% in 2024 and by almost 500% from its lowest level this year.
Novavax (NASDAQ: NVAX ) is on a recovery trek after collapsing in late 2021. Recently, management said that its latest vaccine version addressing newer Covid-19 subvariants is more effective than older injections.
An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has started manufacturing that targets a variant that was dominant earlier this year, the company said.